ABK Biomedical

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, ABK Biomedical sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials none currently recruiting upper half by trial count

ABK Biomedical: 1 sponsored US clinical trial, none currently recruiting.

ABK Biomedical sponsors 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. The most-studied condition in this pipeline is Hepatocellular Carcinoma Non-resectable, with 1 trials.

Mid-pack sponsor footprint

ABK Biomedical is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Indexed trials (enrollment closed)

1 total, page 1 of 1

ACTIVE NOT RECRUITING NA

Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)

NCT05953337

Therapeutic Areas

Hepatocellular Carcinoma Non-resectable 1
Liver Cancer 1
Hepatocellular Carcinoma 1

How the ABK Biomedical archive is shaped

1 indexed studies, none listed as recruiting (0% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Hepatocellular Carcinoma Non-resectable (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

ABK Biomedical: archived-pipeline peers nationwide

Peers matched on 1 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

ABK Biomedical sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60% Total trials Recruiting share ABK Biomedical1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health10xBio22nd Century Group23andMe3-C Institute for Social Development
ABK Biomedical sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

ABK Biomedical sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this ABK Biomedical page

1 registered trials is a research-attention snapshot, not an endorsement of ABK Biomedical or any single study.

  • None of ABK Biomedical's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Hepatocellular Carcinoma Non-resectable is the condition ABK Biomedical studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hepatocellular Carcinoma Non-resectable trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. ABK Biomedical pipeline card: 1 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.